Replies to post #133252 on Biotech Values

[DewDiligence]

Probably does not bode well for the RLS market.

I think we can remove the word probably. The cost of seeking registration for the new indication is trivial for a company like PFE, so the commercial opportunity must be very small indeed.

p.s. Patent protection is not the issue, evidently. Lyrica has Orange Book patents that run until Dec 2018.